Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Elizabeth Manchen"'
Autor:
Edwin M. Posadas, Walter M. Stadler, Elizabeth K. Chung, Kristen Kasza, Theodore Karrison, Olwen Hahn, Elizabeth Manchen
Publikováno v:
American Journal of Clinical Oncology. 34:150-154
Renal cancer accounts for approximately 58,000 (4%) of new noncutaneous cancer cases and is estimated to result in approximately 13,000 deaths in the United States in 2009.1 The introduction of mTOR and vascular endothelial growth factor (VEGF) pathw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::394e7d8d5a11e876ce1caf96a0ba7879
https://doi.org/10.1097/coc.0b013e3181d6b2fe
https://doi.org/10.1097/coc.0b013e3181d6b2fe
Autor:
Milica Medved, Theodore Karrison, Olwen Hahn, Cheng Yang, Myrosia T. Mitchell, Mark J. Ratain, Elizabeth Manchen, Walter M. Stadler, Gregory S. Karczmar, Emily O. Kistner
Publikováno v:
Journal of Clinical Oncology. 26:4572-4578
Purpose Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate dynamic contrast magnetic resonance imaging (DCE-MRI) as a pharmacodynamic biomarker. Patients and Methods Patients were random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbecf57678515bc0fddb19cb33d41e81
https://doi.org/10.1200/jco.2007.15.5655
https://doi.org/10.1200/jco.2007.15.5655
Autor:
Elizabeth Manchen
Publikováno v:
Seminars in Oncology Nursing. 23:S11-S14
Objectives To review the treatment options for advanced or metastatic bladder cancer, including novel agents. Data Sources Research literature and clinical trial data. Conclusion Knowledge of current and novel therapies for the treatment of advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f96283dc24aaef04ceab04a0869b770
https://doi.org/10.1016/j.soncn.2007.10.008
https://doi.org/10.1016/j.soncn.2007.10.008
Publikováno v:
The journal of supportive oncology. 9(1)
One significant toxicity associated with the anticancer tyrosine kinase inhibitors (TKIs) is hand-foot skin reaction (HFSR). We provide an overview of HFSR, emphasizing experience-based prevention techniques and nursing management strategies from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a14b719347071e4b6fba5f8534c9d74
https://pubmed.ncbi.nlm.nih.gov/21465734
https://pubmed.ncbi.nlm.nih.gov/21465734
Autor:
Supriya G. Mohile, Russell Z. Szmulewitz, Edwin M. Posadas, Walter M. Stadler, Theodore Karrison, Elizabeth Manchen, Rangesh Kunnavakkam
Publikováno v:
European urology. 56(1)
Background Even in castration-resistant prostate cancer (CRPC), the androgen pathway remains biologically relevant. In preclinical models, androgen therapy for CRPC leads to growth arrest, apoptosis, and tumor shrinkage. Objective This study sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e92b75c0a3493127bac3c1746740b32a
https://pubmed.ncbi.nlm.nih.gov/19683856
https://pubmed.ncbi.nlm.nih.gov/19683856
Autor:
Kristen Kasza, Edwin M. Posadas, Walter M. Stadler, Elizabeth K. Chung, L. Michalak, Theodore Karrison, Olwen Hahn, Elizabeth Manchen
Publikováno v:
Journal of Clinical Oncology. 27:e16072-e16072
e16072 Background: RCC is resistant to most traditional DNA and DNA repair targeted chemotherapy; although modest response rates to nucleotide analog based therapy, including GC, have been reported. Bevacizumab has activity in RCC. We thus performed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c917a32656da5121971c4de078d7f16
https://doi.org/10.1200/jco.2009.27.15_suppl.e16072
https://doi.org/10.1200/jco.2009.27.15_suppl.e16072
Publikováno v:
Journal of Clinical Oncology. 25:15584-15584
15584 Background: Transition to the castrate resistant state may be due, in part, to the development of a more sensitive and promiscuous androgen receptor (AR) pathway. Androgen therapy of CRPC leads to growth arrest and tumor shrinkage in preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::338a5c17b94bbbdb31ade70783ece8a5
https://doi.org/10.1200/jco.2007.25.18_suppl.15584
https://doi.org/10.1200/jco.2007.25.18_suppl.15584